ISOFOL Stock Overview
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally.
Isofol Medical AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr1.28|
|52 Week High||kr14.44|
|52 Week Low||kr1.08|
|1 Month Change||-83.85%|
|3 Month Change||-86.21%|
|1 Year Change||-85.32%|
|3 Year Change||-94.73%|
|5 Year Change||-94.17%|
|Change since IPO||-95.27%|
Recent News & Updates
|ISOFOL||SE Biotechs||SE Market|
Return vs Industry: ISOFOL underperformed the Swedish Biotechs industry which returned -21.2% over the past year.
Return vs Market: ISOFOL underperformed the Swedish Market which returned -21.8% over the past year.
|ISOFOL Average Weekly Movement||25.3%|
|Biotechs Industry Average Movement||8.7%|
|Market Average Movement||7.1%|
|10% most volatile stocks in SE Market||12.3%|
|10% least volatile stocks in SE Market||4.5%|
Stable Share Price: ISOFOL is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: ISOFOL's weekly volatility has increased from 15% to 25% over the past year.
About the Company
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital.
Isofol Medical AB (publ) Fundamentals Summary
|ISOFOL fundamental statistics|
Is ISOFOL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ISOFOL income statement (TTM)|
|Cost of Revenue||kr196.71m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 23, 2022
|Earnings per share (EPS)||-1.24|
|Net Profit Margin||-893.70%|
How did ISOFOL perform over the long term?See historical performance and comparison